Member Info for Divvyup

20 days from binding agreement would equal IM delivery 29th Aug.
Hmmm, AZ might get hammered on Monday, so I’ll go for Tuesday 30th :-)

I don`t hover over sp on here, more the close.
It would be more interesting if day traders we coloured coded green on buying.
Amused that on no news as soon as those 0.10/1s appear most blues would show up as green.
On selling a brown colour comes to mind :-)

Not concerned about raising capital in this context.
PHE has a window of opportunity with today’s announcement. A strong media push to stem what appears to be an increasing subservient presence within this partnership?
The counter to this opinion is it may undermine the US waste too hydrogen road show. The US do have a reputation of cutting out the middleman (woman) and no lack of funding if they see a $ sign.
Too complicated for me. Tempus narrabo.
Thanks to all contributors.

(HUI) statement “its technology” “our technology”
No mention of DMG.
PHE “adopted policy of holding”
“HUI /PHE (Investment) “recovered through an appropriate mechanism to be agreed”.
Does this change or set a precedent to the future PHE 500,000 license model?
As an investor in PHE, am I wrong to be concerned?

Cheers MJ
Re CF Fertilizers/Biochar: Getting a balance between demand and environmental consideration is never easy.
Once again, the cost of power plays a part in lost jobs plus threatens Industry, food and beer price inflation.
https://www.cheshire-live.co.uk/news/chester-cheshire-news/could-cheshire-co2-factory-closure-24177626
The birds will fly, just wish I had the means to migrate with them, Just for the winter :-)

DMG by-product Biochar, An income stream with growth potential.
https://greenstories.co.in/could-humble-biochar-big-carbon-climate-change/
https://www.transparencymarketresearch.com/us-biochar-market.html
Under valued IMO.
GLA

Hiring RE manufacturing scale-up of its new product.
https://www.seek.com.au/job/58112512?type=standard#sol=9caaa5de9d2f52841b827500730a5076d5293c57
GLA

Note: Share holding ref Date is 1st April 22. Believe next udate for this data will be Sept :-)

Just to clarify
Dec 24 2020 RNS Number : 8006J
Mr. Zamboni will be the beneficial owner of the AvantGarde Group, post-merger. The percentage stated does not include the 17.99% of SYME shares related to the collateral transferred in accordance with the three stock-lending transactions announced on 29 July 2020. At the end of this stock-lending transaction or on the repayment date (in July 2022, now 23 /27), the collateral will be returned to the Group in shares or cash, at the choice of the borrower.
All goes back to this
https://globallegalchronicle.com/ceo-alessandro-zambonis-e91-million-repurchase-of-100-interest-in-the-avantgarde-group-s-p-a/
In abit of a rush so apologies for typo's.
Fingers crossed for progress re Vechainthor and my best wishes to all those invested.

Apologiesprevious post "RUBBISH" should have been the Subject Title..

RUBBISH..
In order to cover the 91m buy out (1AF2 “the company”) Transferred as a loan security 5,893,824,429 shares = £35,362,946.57 2 Due @ july 23 +1 @ 2027
Current value £6,777,898.09 AZs down 28.5 M+ on his 1AF2 loan.
(1AF2) currently hold 12,742,513,009 (SYME.L ) @ 0.006p @entry = £76,455,078 (based on 91M Euros Purchase price)
Current value £15.6m
AZ needs a 400% rise to cover his original entry point.
1AF2 as “the company” is an investor in SME.L , IT IS NOT SYME.L merely another company belonging to AZ.

Chris Evans philosophy and business model are simple. Ask pharma what it wants then structure the research/trials accordingly (his own statement). Structure usually means a new company. Too early to say whether vela will be involved or want to. whichever direction funding takes this has now become much more than treating COVID /T2DM more immunosuppression, inflammatory treatments via Tregs (T Cells).

Fun research.
{{:-)) Early days: you never know I might be taking the first ADZ1656 based anti-aging drug in 10-15 years.
https://link.springer.com/article/10.1007/s00109-022-02193-4
GLA

Vela may be negotiating, but its on potential only not a product.
Inlay man’s terms, 58% success rate on phase 3 trials with 20% failure due to lack of funding.
Parma has more cowboys that a rodeo.

Ha Ha Lvu33: Love the enthusiasm… I don’t think vela is on its own on this and doubt it has a spare £20 million for Phase 3. That’ll be another 4 year wait as they target 1 – 3 thousand patients in various geographical locations. Phase 4 before you can determine long term effects another 7 year wait. Then of to market it goes pending demand. In the meantime I’ve got to get dinner on the table.
:-))))

Quote “larger clinical trial is now required”
View as a positive start and earlier than i predicted (Sept).
Question is will Vela attempt to sell out early or hold out for a larger stage 3 trial?
IMO With the Transplant trial @ Queen Mary Uni also progressing selling up at this stage would minimise risk but also potential.
GLA

Chastroll: Thanks, this raises a further question will warrants be part of the calculations?

Ha Ha, No frosty connotations whatsoever. I Thought you were implying they were hiring ;-)
Ho hum.

Ex: Care to share recent info Re "Wouldn't be hiring if there was no job for them to do now would we ;-)."
Cheers.

BenFou86: Now thats what I call posting. Thanks for all your hard work.
Enjoy
https://video.twimg.com/ext_tw_video/1559438043605524481/pu/vid/720x956/uy-cI-Fc_DZQKfSa.mp4?tag=12

00 Would love to know the take up from the coms
HBOS Investment Fund Managers Limited
A J Bell Holdings Limited, Asset Management Arm
IG Group Holdings Plc, Asset Management Arm
Barclays Bank PLC, Wealth and Investment Management Division
Pictet & Cie (Europe) S.A., Asset Management Arm